Cargando…

Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement

BACKGROUND: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Gallego Albertos, Celia, Del Castillo Pardo de Vera, José Luis, Viejo Llorente, Aurora, Cebrián Carretero, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601641/
https://www.ncbi.nlm.nih.gov/pubmed/34704981
http://dx.doi.org/10.4317/medoral.24007
_version_ 1784601399397449728
author Sánchez-Gallego Albertos, Celia
Del Castillo Pardo de Vera, José Luis
Viejo Llorente, Aurora
Cebrián Carretero, José Luis
author_facet Sánchez-Gallego Albertos, Celia
Del Castillo Pardo de Vera, José Luis
Viejo Llorente, Aurora
Cebrián Carretero, José Luis
author_sort Sánchez-Gallego Albertos, Celia
collection PubMed
description BACKGROUND: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP) placement in MRONJ patients. MATERIAL AND METHODS: Seventy MRONJ patients treated at the department of Oral and Maxillofacial Surgery in La Paz Hospital (Madrid, Spain) were included in this retrospective study. All of them were treated surgically by local debridement and PRP placement. The observation period was between January 2012 and January 2019. Information regarding use, type, administration, and duration of therapy with BP/denosumab was recorded. The follow-up period ranged from 2-52 months. A descriptive analysis, a bivariate and a multivariate study were performed. RESULTS: Most of the patients were women (82.9%) between 50-70 years old (64.3%), with a stage II disease (74.3%). The therapy lasted more than 12 months in 54.8% of them. Zoledronic acid was the main antiresorptive used (44.3%), followed by oral administered BPs (29 patients, 41.4%) and denosumab (10 patients, 14.3%). Osteoporosis (48.6%), breast cancer (30%) and multiple myeloma (11.4%) were the main diseases because the patients were taking antirresorptives. 13 patients (18.6%) experienced recurrence. We found that breast cancer patients (p>0.0001), smokers (p>0.016), and administration of zoledronic acid (p>0.0001) were related to recurrence. After performing the multivariate model, we found that the only factor related to recurrence was smoking habit (Wald 3.837, p=0.05, OR 6.12). CONCLUSIONS: recurrence after local debridement plus PRP placement in our MRONJ series affected to 18.6% of patients. It seems to be more frequent in breast cancer patients, smokers, and after zoledronic acid administration. Smoking habit was the only independent factor related to recurrence in our series. Key words:Osteonecrosis of the jaw, recurrence, risk factor, bisphosphonates, zoledronic acid, denosumab, platelet rich plasma.
format Online
Article
Text
id pubmed-8601641
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Medicina Oral S.L.
record_format MEDLINE/PubMed
spelling pubmed-86016412021-11-24 Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement Sánchez-Gallego Albertos, Celia Del Castillo Pardo de Vera, José Luis Viejo Llorente, Aurora Cebrián Carretero, José Luis Med Oral Patol Oral Cir Bucal Research BACKGROUND: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP) placement in MRONJ patients. MATERIAL AND METHODS: Seventy MRONJ patients treated at the department of Oral and Maxillofacial Surgery in La Paz Hospital (Madrid, Spain) were included in this retrospective study. All of them were treated surgically by local debridement and PRP placement. The observation period was between January 2012 and January 2019. Information regarding use, type, administration, and duration of therapy with BP/denosumab was recorded. The follow-up period ranged from 2-52 months. A descriptive analysis, a bivariate and a multivariate study were performed. RESULTS: Most of the patients were women (82.9%) between 50-70 years old (64.3%), with a stage II disease (74.3%). The therapy lasted more than 12 months in 54.8% of them. Zoledronic acid was the main antiresorptive used (44.3%), followed by oral administered BPs (29 patients, 41.4%) and denosumab (10 patients, 14.3%). Osteoporosis (48.6%), breast cancer (30%) and multiple myeloma (11.4%) were the main diseases because the patients were taking antirresorptives. 13 patients (18.6%) experienced recurrence. We found that breast cancer patients (p>0.0001), smokers (p>0.016), and administration of zoledronic acid (p>0.0001) were related to recurrence. After performing the multivariate model, we found that the only factor related to recurrence was smoking habit (Wald 3.837, p=0.05, OR 6.12). CONCLUSIONS: recurrence after local debridement plus PRP placement in our MRONJ series affected to 18.6% of patients. It seems to be more frequent in breast cancer patients, smokers, and after zoledronic acid administration. Smoking habit was the only independent factor related to recurrence in our series. Key words:Osteonecrosis of the jaw, recurrence, risk factor, bisphosphonates, zoledronic acid, denosumab, platelet rich plasma. Medicina Oral S.L. 2021-11 2021-10-27 /pmc/articles/PMC8601641/ /pubmed/34704981 http://dx.doi.org/10.4317/medoral.24007 Text en Copyright: © 2021 Medicina Oral S.L. https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Sánchez-Gallego Albertos, Celia
Del Castillo Pardo de Vera, José Luis
Viejo Llorente, Aurora
Cebrián Carretero, José Luis
Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
title Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
title_full Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
title_fullStr Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
title_full_unstemmed Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
title_short Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
title_sort medication related osteonecrosis of the jaws (mronj): factors related to recurrence after treatment with surgery and platelet rich plasma (prp) placement
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601641/
https://www.ncbi.nlm.nih.gov/pubmed/34704981
http://dx.doi.org/10.4317/medoral.24007
work_keys_str_mv AT sanchezgallegoalbertoscelia medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement
AT delcastillopardodeverajoseluis medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement
AT viejollorenteaurora medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement
AT cebriancarreterojoseluis medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement